[Current questions in the radiotherapy of lymphoproliferative tumors]

Radiation therapy traditionally plays a major role in the treatment of lymphoproliferative diseases. Diagnostics and treatment of these tumors improved tremendously in the recent decades. Molecular diagnostics is able to discriminate its subtypes more precisely than ever and opens the possibility of the introduction of targeted medicines. Imaging, especially functional imaging now has an established role in forming treatment strategy. Radiation therapy showed substantial technical development too. As a consequence of these, the role, dose and technique of radiotherapy changes instantly. In this short review we discuss situations which clinicians, both hemato-oncologists and radiation oncologist may face day by day. These are: the changing role of radiation therapy in early Hodgkin's disease, including dose and filed size reduction and PET-driven radiation therapy; the use of radiation in advanced Hodgkin's disease; the role of radiation therapy of diffuse large B-cell lymphoma in the light of the use of rituximab; and finally the use of modern radiation therapy techniques like intensity-modulated radiation therapy or particle therapy.